Do glucocorticoids suppress pro-inflammatory signaling and keep CRP low despite immune cell activation?

The claim that glucocorticoids suppress pro-inflammatory signaling and maintain low C-reactive protein (CRP) levels despite immune cell activation is strongly supported by clinical and mechanistic evidence. This phenomenon often creates a "clinical discordance" where traditional inflammatory markers do not accurately reflect the patient's underlying physiological state.

Mechanistic explanations

Glucocorticoids (GCs) disrupt inflammatory signaling through several convergent molecular pathways:

• Transcriptional interference: The glucocorticoid receptor (GR) undergoes transrepression, directly interfering with key pro-inflammatory transcription factors like NF-κB and AP-1, which are essential for cytokine production.
• JAK/STAT inhibition: GCs inhibit the JAK/STAT signaling pathway, specifically blocking the phosphorylation and DNA-binding capacity of STAT3. Since STAT3 is the primary driver of IL-6-mediated gene expression in the liver, its inhibition directly halts the production of acute-phase proteins.
• Hepatic modulation: GCs upregulate Suppressors of Cytokine Signaling (SOCS-1 and SOCS-2) within hepatocytes. This enhances the negative feedback loop that dampens the liver's response to circulating cytokines like IL-6 and TNF-α.

Clinical evidence and discordance

Glucocorticoid administration frequently results in a rapid and significant reduction in serum CRP levels, often within 72 hours of treatment, across conditions such as rheumatoid arthritis and severe infections.

• Leukocytosis vs. CRP: While CRP is suppressed, GCs simultaneously induce leukocytosis (elevated white blood cell counts). This occurs through "demargination," where neutrophils are released from the vascular endothelium into the bloodstream due to reduced expression of endothelial selectins.
• Diagnostic masking: Because GCs effectively decouple the relationship between immune cell presence and acute-phase protein synthesis, CRP cannot be used as a reliable standalone marker of infection or inflammation in patients receiving steroid therapy.

Bottom line

Glucocorticoids suppress the hepatic acute-phase response and CRP production by inhibiting the IL-6/STAT3 pathway and inducing SOCS proteins. Clinicians should be aware that a low CRP in a patient on glucocorticoids does not necessarily rule out active inflammation or infection, especially when paired with steroid-induced leukocytosis.